Podcasts about CRC

Volvemos al mundo de las Leyendas Urbanas, pero más bien, nos centramos en las Creepypastas, en los orígenes de las historias tenebrosas que uno puede imaginar... Y lo hacemos con las historias de: "The Nurse Ann", "The Rake" y "El origen de Slenderman". Muchas gracias a los actores de doblaje que han participado en este capítulo: - GEMMA ESTEBAN - PABLO DÍEZ @P1Dubber (Twitter) @diezpablo10 (Instagram) - ALBERTO MARTÍNEZ @arbolesxhora (Twitter e Instagram) - JOSE LUIS GARCÍA @alaguair70 (Twitter) @alaguair (Instagram) Por supuesto gracias a todos vosotros, mecenas por acompañarnos sin parar. ¡Sois los mejores! Camarzana1, José Manuel D. G., Consuelo, Laura D., Ramiro C., Samuel C., Ana C., Clara R., Lara M., Claudia, Xavito B., Laura, Iván De Benito P., Marcos M. V., Naiara G. G., TorpeKun, Míriam Z., Sara S. C., Eva V., Paloma del Soterraño S. M., Ferran B. L., Fernando F. M., José Antonio M. H., Patri J., Sandra S. C., Antonio A., Sara D., Beatriz G., Mónica M., Maxbiag, Carmen S. S., Raquel., Rocio B., Alejandro L. G., Sebastian Q., Lorena R. T., Nox21, Andréa E., Víctor I., Alba R., Diego G., Raul M. G., Klap K., Julia E. S., Jonathan L. G., Noelia M., Jose C., David G. A., Virginia, Nardo1000, Diego C. A., Mayte S.M., Cynthia, Homero R. D. C., Desirée G. A., Miguel Ángel S., Andres C., Antonio S. M., Vero, Ana, Yaiza M. G., Piteas De Adunte, Manuel Jesús F. V., Ian T. A., Felix R. G., Jaime A. B., Natalia E. N., Pep V., Alejandro, Adrián A. C., Vicco S., Nico, Beatriz S., Juan Carlos V. P., Carla, Manuel G. C., Adrian, Ángel M. CRC., Moreyba S., Inés B. P., Patricia, Maciej Adrián R. A., Borja O. D. U., Pedro O. A., Daniela G., Blegoner P., Antonino D. M., Belén L. M., Andrea D., Robert, Marta G., Nonina, Cuervo Aqua, Tamara, Sara P., Maite Y., Raquel N., Hellnukk, Iris, Miriam S. G., David G. A., Vanesa, Rut, Maria Merino P. D. R., Merce A., Sergio N., Maria Ignacia V., Laura S., Ezequiel Y., HumaDracobane, M Moar, Aleix C., Regina G. M., Alejandra A., Alba, Erika T., Dahmm22, Guardi C. G., Alejandro F. P., Clara, Julia Salomon, Angel, Lionmind, Broke S., Thehob, Natanael C. S., Judith P. C., José A., David, Barbara P. J., Laura R., Patricia O. P., Arianna T. M., Juan L., Ana, Mariana D., Carlos Javier V. B., Sofía, Oscar Mata G. D. C., Marta B., Javier A. S., José Luis H. M., Chris, Ramiro, Victor N., Micaela, Joan Marc P. S., Miguel Diego A. C., Javier M. P., Mafdet23, Nina S., Yara, Patricia L. C., Laura N., Carmen, Bea T., Javier C., Marino Adolfo B. A., Dg, Bea G., Jorge H., Ismael G., Paula S., Nicole N., Rebeca P., AlvaroArteaga27, Alexander J. G., Kumagoro 93, Carlos E., Sheila G., Francisca C. V., Beto L. O., Luis M., Lucia G., Marcela V., Joey B., Mireia S., Rubén G., Vikki V., María Cecilia C. V., Fran M., Eva L. F., Jose J., Inma, Juan Miguel P. P., marenostrum93, Moar Moar L., Victor E., Vale C., Juan M, Angie V., Orion M., Nerea N., Neah, Alicia B., Lisa M., David S. A., Fani, Ika, Ismael R., Moreno B. A., Laura M. ¿Quieres contactar con nosotros? Tiktok: @terroresnocturnos.trn Twitter: @TerroresN Instagram: @terroresnocturnos_trn Twitch: TerroresNocturnos_trn Instagram Emma Entrena: @emma.e_trn Instagram Silvia Ortiz: @sil_trn Instagram David Fernández Marcos: @davidfm55 Instagram The Gray: @thegray.art Facebook: Terrores Nocturnos Correo: terroresnocturnosradio@gmail.com Realizado por David Fernández Marcos Presentado por Emma Entrena y Silvia Ortiz Ilustración de TheGray.art --- Send in a voice message: https://anchor.fm/terroresnocturnos/message

Support us on Patreon: https://www.patreon.com/themessyreformation?fan_landing=true   Check out our website: https://themessyreformation.jasonruis.com   Check out the Abide Project:  https://www.abideproject.org   We love the Christian Reformed Church; we want to see reformation in our denomination; and we recognize that reformation is typically messy. So, we're having conversations with pastors throughout the CRC about what reformation might look like.   Intro Music by Matt Krotzer

En este capítulo os hablaremos de una de las mansiones más encantadas del mundo, construido casi por "obligación" por su dueña: Sarah Winchester, esposa de William Winchester, creador de la reconocida escopeta "Winchester"; ¿Tendrá alguna relación este arma, con la propia mansión? Muchas gracias a la actriz de doblaje que ha participado en el capítulo: - GEMMA ESTEBAN Por supuesto gracias a todos vosotros, mecenas por acompañarnos sin parar. ¡Sois los mejores! Camarzana1, José Manuel D. G., Consuelo, Laura D., Ramiro C., Samuel C., Ana C., Clara R., Lara M., Claudia, Xavito B., Laura, Iván De Benito P., Marcos M. V., Naiara G. G., TorpeKun, Míriam Z., Sara S. C., Eva V., Paloma del Soterraño S. M., Ferran B. L., Fernando F. M., José Antonio M. H., Patri J., Sandra S. C., Antonio A., Sara D., Beatriz G., Mónica M., Maxbiag, Carmen S. S., Raquel., Rocio B., Alejandro L. G., Sebastian Q., Lorena R. T., Nox21, Andréa E., Víctor I., Alba R., Diego G., Raul M. G., Klap K., Julia E. S., Jonathan L. G., Noelia M., Jose C., David G. A., Virginia, Nardo1000, Diego C. A., Mayte S.M., Cynthia, Homero R. D. C., Desirée G. A., Miguel Ángel S., Andres C., Antonio S. M., Vero, Ana, Yaiza M. G., Piteas De Adunte, Manuel Jesús F. V., Ian T. A., Felix R. G., Jaime A. B., Natalia E. N., Pep V., Alejandro, Adrián A. C., Vicco S., Nico, Beatriz S., Juan Carlos V. P., Carla, Manuel G. C., Adrian, Ángel M. CRC., Moreyba S., Inés B. P., Patricia, Maciej Adrián R. A., Borja O. D. U., Pedro O. A., Daniela G., Blegoner P., Antonino D. M., Belén L. M., Andrea D., Robert, Marta G., Nonina, Cuervo Aqua, Tamara, Sara P., Maite Y., Raquel N., Hellnukk, Iris, Miriam S. G., David G. A., Vanesa, Rut, Maria Merino P. D. R., Merce A., Sergio N., Maria Ignacia V., Laura S., Ezequiel Y., HumaDracobane, M Moar, Aleix C., Regina G. M., Alejandra A., Alba, Erika T., Dahmm22, Guardi C. G., Alejandro F. P., Clara, Julia Salomon, Angel, Lionmind, Broke S., Thehob, Natanael C. S., Judith P. C., José A., David, Barbara P. J., Laura R., Patricia O. P., Arianna T. M., Juan L., Ana, Mariana D., Carlos Javier V. B., Sofía, Oscar Mata G. D. C., Marta B., Javier A. S., José Luis H. M., Chris, Ramiro, Victor N., Micaela, Joan Marc P. S., Miguel Diego A. C., Javier M. P., Mafdet23, Nina S., Yara, Patricia L. C., Laura N., Carmen, Bea T., Javier C., Marino Adolfo B. A., Dg, Bea G., Jorge H., Ismael G., Paula S., Nicole N., Rebeca P., AlvaroArteaga27, Alexander J. G., Kumagoro 93, Carlos E., Sheila G., Francisca C. V., Beto L. O., Luis M., Lucia G., Marcela V., Joey B., Mireia S., Rubén G., Vikki V., María Cecilia C. V., Fran M., Eva L. F., Jose J., Inma, Juan Miguel P. P., marenostrum93, Moar Moar L., Victor E., Vale C., Juan M, Angie V., Orion M., Nerea N., Neah, Alicia B., Lisa M., David S. A., Fani, Ika, Ismael R., Moreno B. A., Laura M. ¿Quieres contactar con nosotros? Tiktok: @terroresnocturnos.trn Twitter: @TerroresN Instagram: @terroresnocturnos_trn Twitch: TerroresNocturnos_trn Instagram Emma Entrena: @emma.e_trn Instagram Silvia Ortiz: @sil_trn Instagram David Fernández Marcos: @davidfm55 Instagram The Gray: @thegray.art Facebook: Terrores Nocturnos Correo: terroresnocturnosradio@gmail.com Realizado por David Fernández Marcos Presentado por Emma Entrena y Silvia Ortiz Ilustración de TheGray.art --- Send in a voice message: https://anchor.fm/terroresnocturnos/message

Support us on Patreon: https://www.patreon.com/themessyreformation?fan_landing=true   Check out our website: https://themessyreformation.jasonruis.com   Check out the Abide Project:  https://www.abideproject.org   We love the Christian Reformed Church; we want to see reformation in our denomination; and we recognize that reformation is typically messy. So, we're having conversations with pastors throughout the CRC about what reformation might look like.   Intro Music by Matt Krotzer

Support us on Patreon: https://www.patreon.com/themessyreformation?fan_landing=true   Check out our website: https://themessyreformation.jasonruis.com   Check out the Abide Project:  https://www.abideproject.org   We love the Christian Reformed Church; we want to see reformation in our denomination; and we recognize that reformation is typically messy. So, we're having conversations with pastors throughout the CRC about what reformation might look like.   Intro Music by Matt Krotzer

En este especial de Halloween os traemos el primer capítulo realizado en directo a través de nuestro canal de Twitch, TerroresNocturnos_trn, y os contamos las historias escritas por Charles Dickens y W. W. Jacobs: "El Guardavía", y "la Pata de Mono". Por supuesto gracias a todos nuestros mecenas que nos habéis acompañado en esta tercera temporada ¡Sois los mejores! Camarzana1, José Manuel D. G., Consuelo, Laura D., Ramiro C., Samuel C., Ana C., Clara R., Lara M., Claudia, Xavito B., Laura, Iván De Benito P., Marcos M. V., Naiara G. G., TorpeKun, Míriam Z., Sara S. C., María Jesús B., Eva V., Paloma del Soterraño S. M., Ferran B. L., Fernando F. M., José Antonio M. H., Patri J., Sandra S. C., Antonio A., Sara D., Beatriz G., Mónica M., Maxbiag, Carmen S. S., Raquel., Rocio B., Alejandro L. G., Sebastian Q., Lorena R. T., Nox21, Andréa E., Víctor I., Alba R., Diego G., Raul M. G., Klap K., Miguel Ángel S. G., Julia E. S., Jonathan L. G., Noelia M., Jose C., David G. A., Virginia, Nardo1000, Diego C. A., Mayte S.M., Cynthia, Homero R. D. C., Desirée G. A., Miguel Ángel S., Andres C., Antonio S. M., Vero, Ana, Yaiza M. G., Piteas De Adunte, Manuel Jesús F. V., Ian T. A., Felix R. G., David Z., Jaime A. B., Natalia E. N., Pep V., Alejandro, Adrián A. C., Vicco S., Nico, Beatriz S., Juan Carlos V. P., Carla, Manuel G. C., Adrian, Ángel M. CRC., Moreyba S., Inés B. P., Patricia, Maciej Adrián R. A., Borja O. D. U., Pedro O. A., Daniela G., Blegoner P., Antonino D. M., Belén L. M., Andrea D., Robert, Marta G., Nonina, Cuervo Aqua, Tamara, Sara P., María R. M., Maite Y., Raquel N., Hellnukk, Iris, Miriam S. G., David G. A., Vanesa, Rut, Maria Merino P. D. R., Merce A., Sergio N., Maria Ignacia V., Laura S., Ezequiel Y., HumaDracobane, M Moar, Alvaro S. C., Aleix C., Regina G. M., Alejandra A., Alba, Erika T., Sandra A. L., Dahmm22, Guardi C. G., Alejandro F. P., Elena, Clara, Julia Salomon, Angel, Lionmind, Broke S., Thehob, Natanael C. S., Judith P. C., José A., David, Barbara P. J., Laura R., Patricia O. P., Arianna T. M., Juan L., Ana, Mariana D., Carlos Javier V. B., Sofía, Oscar Mata G. D. C., Marta B., Javier A. S., José Luis H. M., Chris, Ramiro, Victor N., Micaela, Joan Marc P. S., Miguel Diego A. C., Javier M. P., Mafdet23, Nina S., Yara, Patricia L. C., Laura N., Carmen, Bea T., Javier C., Marino Adolfo B. A., Dg, Bea G., Jorge H., Ismael G., Paula S., Nicole N., Rebeca P., Ana B., AlvaroArteaga27, Alexander J. G., Kumagoro 93, Carlos E., Sara C.Labrada, Jose Angel C. L., Sheila G., Francisca C. V., SYNL, Beto L. O., Luis M., Lucia G., Marcela V., Joey B., Mireia S., T. Kuznetsov, Patricia C. R., Rubén G., Vikki V., María Cecilia C. V., Srtanognog., Fran M., Eva L. F., Jose J., Inma, Juan Miguel P. P., marenostrum93, Moar Moar L., Victor E. ¿Quieres contactar con nosotros? Tiktok: @terroresnocturnos.trn Twitter: @TerroresN Instagram: @terroresnocturnos_trn Twitch: TerroresNocturnos_trn Instagram Emma Entrena: @emma.e_trn Instagram Silvia Ortiz: @sil_trn Instagram David Fernández Marcos: @davidfm55 Instagram The Gray: @thegray.art Facebook: Terrores Nocturnos Correo: terroresnocturnosradio@gmail.com Realizado por David Fernández Marcos Presentado por Emma Entrena y Silvia Ortiz Ilustración de TheGray.art --- Send in a voice message: https://anchor.fm/terroresnocturnos/message

Support us on Patreon: https://www.patreon.com/themessyreformation?fan_landing=true   Check out our website: https://themessyreformation.jasonruis.com   Check out the Abide Project:  https://www.abideproject.org   We love the Christian Reformed Church; we want to see reformation in our denomination; and we recognize that reformation is typically messy. So, we're having conversations with pastors throughout the CRC about what reformation might look like.   Intro Music by Matt Krotzer

Support us on Patreon: https://www.patreon.com/themessyreformation?fan_landing=true   Check out our website: https://themessyreformation.jasonruis.com   Check out the Abide Project:  https://www.abideproject.org   We love the Christian Reformed Church; we want to see reformation in our denomination; and we recognize that reformation is typically messy. So, we're having conversations with pastors throughout the CRC about what reformation might look like.   Intro Music by Matt Krotzer

Today's guests are Tammy Combs, RN, MSN, CDIP, CCS, CCDS, director of HIM practice excellence, CDI nurse planner at AHIMA, and Laurie Prescott, RN, MSN, CCDS, CCDS-O, CDIP, CRC, interim ACDIS director and director of CDI education for HCPro. Today's show is part of the “Talking CDI” series. In every episode of this series, ACDIS Director of Programming Rebecca Hendren discusses CDI topics with guests including members of the ACDIS Advisory Board or other experienced CDI leaders from around the country to discuss strategic topics related to the state of the industry, where CDI is going, or opportunities for advancement. During today's show, Combs and Prescott discuss the ACDIS/AHIMA Guidelines for Achieving a Compliant Query Practice brief, which was released on Monday, October 10. You can read the practice brief by clicking here. (http://ow.ly/rZSu50L3ABa) Our intro and outro music for the ACDIS Podcast is “medianoche” by Dee Yan-Kay and our ad music is “Take Me Higher” by Jahzzar, both obtained from the Free Music Archive. Have questions about today's show or ideas for a future episode? Contact the ACDIS team at acdis-inquiries@simplifycompliance.com. ACDIS update: Respond to the 2022 CDI Salary Survey by October 31! (http://ow.ly/RTsh50L3APV) Apply for the ACDIS CDI Scholarship program by November 30! (http://ow.ly/pwtG50L3ARZ)

Os traemos uno de los casos más perturbadores que investigó la familia Warren, sobre una niña que le atacó un ente cuando fue al cementerio, a visitar a una amiga suya, con un oscuro final... Muchísimas gracias por la participación a: - ANEYMA LEÓN @aneymaleon (Twitter) - ALEJANDRA CARRIL @aleejandracv (Twitter) @alejandraaacv (Instagram) Por supuesto gracias a todos nuestros mecenas que nos habéis acompañado en esta tercera temporada ¡Sois los mejores! Camarzana1, José Manuel D. G., Consuelo, Laura D., Ramiro C., Samuel C., Ana C., Clara R., Lara M., Claudia, Xavito B., Laura, Iván De Benito P., Marcos M. V., Naiara G. G., TorpeKun, Míriam Z., Sara S. C., María Jesús B., Eva V., Paloma del Soterraño S. M., Ferran B. L., Fernando F. M., José Antonio M. H., Patri J., Sandra S. C., Antonio A., Sara D., Beatriz G., Mónica M., Maxbiag, Carmen S. S., Raquel., Rocio B., Alejandro L. G., Sebastian Q., Lorena R. T., Nox21, Andréa E., Víctor I., Alba R., Diego G., Raul M. G., Klap K., Miguel Ángel S. G., Julia E. S., Jonathan L. G., Noelia M., Jose C., David G. A., Virginia, Nardo1000, Diego C. A., Mayte S.M., Cynthia, Homero R. D. C., Desirée G. A., Miguel Ángel S., Andres C., Antonio S. M., Vero, Ana, Yaiza M. G., Piteas De Adunte, Manuel Jesús F. V., Ian T. A., Felix R. G., David Z., Jaime A. B., Natalia E. N., Pep V., Alejandro, Adrián A. C., Vicco S., Nico, Beatriz S., Juan Carlos V. P., Carla, Manuel G. C., Adrian, Ángel M. CRC., Moreyba S., Inés B. P., Patricia, Maciej Adrián R. A., Borja O. D. U., Pedro O. A., Daniela G., Blegoner P., Antonino D. M., Belén L. M., Andrea D., Robert, Marta G., Nonina, Cuervo Aqua, Tamara, Sara P., María R. M., Maite Y., Raquel N., Hellnukk, Iris, Miriam S. G., David G. A., Vanesa, Rut, Maria Merino P. D. R., Merce A., Sergio N., Maria Ignacia V., Laura S., Ezequiel Y., HumaDracobane, M Moar, Alvaro S. C., Aleix C., Regina G. M., Alejandra A., Alba, Erika T., Sandra A. L., Dahmm22, Guardi C. G., Alejandro F. P., Elena, Clara, Julia Salomon, Angel, Lionmind, Broke S., Thehob, Natanael C. S., Judith P. C., José A., David, Barbara P. J., Laura R., Patricia O. P., Arianna T. M., Juan L., Ana, Mariana D., Carlos Javier V. B., Sofía, Oscar Mata G. D. C., Marta B., Javier A. S., José Luis H. M., Chris, Ramiro, Victor N., Micaela, Joan Marc P. S., Miguel Diego A. C., Javier M. P., Mafdet23, Nina S., Yara, Patricia L. C., Laura N., Carmen, Bea T., Javier C., Marino Adolfo B. A., Dg, Bea G., Jorge H., Ismael G., Paula S., Nicole N., Rebeca P., Ana B., AlvaroArteaga27, Alexander J. G., Kumagoro 93, Carlos E., Sara C.Labrada, Jose Angel C. L., Sheila G., Francisca C. V., SYNL, Beto L. O., Luis M., Lucia G., Marcela V., Joey B., Mireia S., T. Kuznetsov, Patricia C. R., Rubén G., Vikki V., María Cecilia C. V., Srtanognog., Fran M., Eva L. F., Jose J., Inma, Juan Miguel P. P., marenostrum93, Moar Moar L., Victor E. ¿Quieres contactar con nosotros? Tiktok: @terroresnocturnos.trn Twitter: @TerroresN Instagram: @terroresnocturnos_trn Instagram Emma Entrena: @emma.e_trn Instagram Silvia Ortiz: @sil_trn Instagram David Fernández Marcos: @davidfm55 Instagram The Gray: @thegray.art Facebook: Terrores Nocturnos Correo: terroresnocturnosradio@gmail.com Realizado por David Fernández Marcos Presentado por Emma Entrena y Silvia Ortiz Ilustración de TheGray.art Este episodio está patrocinado por Hayu. Dirígete a Hayu.com para comenzar tu prueba gratuita. --- Send in a voice message: https://anchor.fm/terroresnocturnos/message

Check out our new online discipleship course called CREATED Sexuality:  https://themessyreformation.jasonruis.com/the-hall-of-tyrannus/   Support us on Patreon: https://www.patreon.com/themessyreformation?fan_landing=true   Check out our website: https://themessyreformation.jasonruis.com   Check out the Abide Project:  https://www.abideproject.org   We love the Christian Reformed Church; we want to see reformation in our denomination; and we recognize that reformation is typically messy. So, we're having conversations with pastors throughout the CRC about what reformation might look like.   Intro Music by Matt Krotzer

A new research paper was published in Oncotarget's Volume 13 on October 19, 2022, entitled, “Platelet-derived growth factor (PDGF) cross-signaling via non-corresponding receptors indicates bypassed signaling in colorectal cancer.” Platelet-derived growth factor (PDGF) signaling, besides other growth factor-mediated signaling pathways like vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF), seems to play a crucial role in tumor development and progression. Previously, researchers Romana Moench, Martin Gasser, Karol Nawalaniec, Tanja Grimmig, Amrendra K. Ajay, Larissa Camila Ribeiro de Souza, Minghua Cao, Yueming Luo, Petra Hoegger, Carmen M. Ribas, Jurandir M. Ribas-Filho, Osvaldo Malafaia, Reinhard Lissner, Li-Li Hsiao, and Ana Maria Waaga-Gasser, from Harvard Medical School, Shenzhen Traditional Chinese Medicine Hospital, University of Wuerzburg, and Mackenzie Evangelical Faculty of Paraná, recently provided evidence for upregulation of PDGF expression in UICC stage I–IV primary colorectal cancer (CRC) and demonstrated PDGF-mediated induction of PI3K/Akt/mTOR signaling in CRC cell lines. In their new study, the researchers sought to follow up on our previous findings and explore the alternative receptor cross-binding potential of PDGF in CRC. “Our analysis of primary human colon tumor samples demonstrated upregulation of the PDGFRβ, VEGFR1, and VEGFR2 genes in UICC stage I-III tumors.” Immunohistological analysis revealed co-expression of PDGF and its putative cross-binding partners, VEGFR2 and EGFR. The team then analyzed several CRC cell lines for PDGFRα, PDGFRβ, VEGFR1, and VEGFR2 protein expression. They found these receptors to be variably expressed amongst the investigated cell lines. Interestingly, whereas Caco-2 and SW480 cells showed expression of all analyzed receptors, HT29 cells expressed only VEGFR1 and VEGFR2. However, stimulation of HT29 cells with PDGF resulted in upregulation of VEGFR1 and VEGFR2 expression despite the absence of PDGFR expression and mimicked the effect of VEGF stimulation. Moreover, PDGF recovered HT29 cell proliferation under simultaneous treatment with a VEGFR or EGFR inhibitor. “Our results provide some of the first evidence for PDGF cross-signaling through alternative receptors in colorectal cancer and support anti-PDGF therapy as a combination strategy alongside VEGF and EGF targeting even in tumors lacking PDGFR expression.” DOI: https://doi.org/10.18632/oncotarget.28281 Correspondence to: Ana Maria Waaga-Gasser - awaaga@bwh.harvard.edu Keywords: PDGF, VEGFR, EGFR, bypassed signaling, colorectal cancer About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media: Twitter - https://twitter.com/Oncotarget Facebook - https://www.facebook.com/Oncotarget YouTube – www.youtube.com/c/OncotargetYouTube Instagram - https://www.instagram.com/oncotargetjrnl/ LinkedIn - https://www.linkedin.com/company/oncotarget/ Pinterest - https://www.pinterest.com/oncotarget/ LabTube - https://www.labtube.tv/channel/MTY5OA SoundCloud - https://soundcloud.com/oncotarget For media inquiries, please contact: media@impactjournals.com. Oncotarget Journal Office 6666 East Quaker Str., Suite 1A Orchard Park, NY 14127 Phone: 1-800-922-0957 (option 2)

Support us on Patreon: https://www.patreon.com/themessyreformation?fan_landing=true   Check out our website: https://themessyreformation.jasonruis.com   Check out the Abide Project:  https://www.abideproject.org   We love the Christian Reformed Church; we want to see reformation in our denomination; and we recognize that reformation is typically messy. So, we're having conversations with pastors throughout the CRC about what reformation might look like.   Intro Music by Matt Krotzer

Jeffrey Dahmer se considera uno de los asesinos más temidos de la historia. Un hombre que ha sobrepasado los límites, que ha acabado con la vida de personas inocentes, las ha descuartizado e incluso, en el peor de los casos, se ha comido su propia carne... En este capítulo, os contaremos toda su historia. Muchísimas gracias por la participación a: - PABLO DÍEZ @P1Dubber (Twitter) @diezpablo10 (Instagram) - ANEYMA LEÓN @aneymaleon (Twitter) - ALBERTO MARTINEZ @arbolesxhora (Twitter e Instagram) Por supuesto gracias a todos nuestros mecenas que nos habéis acompañado en esta tercera temporada ¡Sois los mejores! Camarzana1, José Manuel D. G., Consuelo, Laura D., Ramiro C., Samuel C., Ana C., Clara R., Lara M., Claudia, Xavito B., Laura, Iván De Benito P., Marcos M. V., Naiara G. G., TorpeKun, Míriam Z., Sara S. C., María Jesús B., Eva V., Paloma del Soterraño S. M., Ferran B. L., Fernando F. M., José Antonio M. H., Patri J., Sandra S. C., Antonio A., Sara D., Beatriz G., Mónica M., Maxbiag, Carmen S. S., Raquel., Rocio B., Alejandro L. G., Sebastian Q., Lorena R. T., Nox21, Andréa E., Víctor I., Alba R., Diego G., Raul M. G., Klap K., Miguel Ángel S. G., Julia E. S., Jonathan L. G., Noelia M., Jose C., David G. A., Virginia, Nardo1000, Diego C. A., Mayte S.M., Cynthia, Homero R. D. C., Desirée G. A., Miguel Ángel S., Andres C., Antonio S. M., Vero, Ana, Yaiza M. G., Piteas De Adunte, Manuel Jesús F. V., Ian T. A., Felix R. G., David Z., Jaime A. B., Natalia E. N., Pep V., Alejandro, Adrián A. C., Vicco S., Nico, Beatriz S., Juan Carlos V. P., Carla, Manuel G. C., Adrian, Ángel M. CRC., Moreyba S., Inés B. P., Patricia, Maciej Adrián R. A., Borja O. D. U., Pedro O. A., Daniela G., Blegoner P., Antonino D. M., Belén L. M., Andrea D., Robert, Marta G., Nonina, Cuervo Aqua, Tamara, Sara P., María R. M., Maite Y., Raquel N., Hellnukk, Iris, Miriam S. G., David G. A., Vanesa, Rut, Maria Merino P. D. R., Merce A., Sergio N., Maria Ignacia V., Laura S., Ezequiel Y., HumaDracobane, M Moar, Alvaro S. C., Aleix C., Regina G. M., Alejandra A., Alba, Erika T., Sandra A. L., Dahmm22, Guardi C. G., Alejandro F. P., Elena, Clara, Julia Salomon, Angel, Lionmind, Broke S., Thehob, Natanael C. S., Judith P. C., José A., David, Barbara P. J., Laura R., Patricia O. P., Arianna T. M., Juan L., Ana, Mariana D., Carlos Javier V. B., Sofía, Oscar Mata G. D. C., Marta B., Javier A. S., José Luis H. M., Chris, Ramiro, Victor N., Micaela, Joan Marc P. S., Miguel Diego A. C., Javier M. P., Mafdet23, Nina S., Yara, Patricia L. C., Laura N., Carmen, Bea T., Javier C., Marino Adolfo B. A., Dg, Bea G., Jorge H., Ismael G., Paula S., Nicole N., Rebeca P., Ana B., AlvaroArteaga27, Alexander J. G., Kumagoro 93, Carlos E., Sara C.Labrada, Jose Angel C. L., Sheila G., Francisca C. V., SYNL, Beto L. O., Luis M., Lucia G., Marcela V., Joey B., Mireia S., T. Kuznetsov, Patricia C. R., Rubén G., Vikki V., María Cecilia C. V., Srtanognog., Fran M., Eva L. F., Jose J., Inma, Juan Miguel P. P., marenostrum93, Moar Moar L., Victor E. ¿Quieres contactar con nosotros? Tiktok: @terroresnocturnos.trn Twitter: @TerroresN Instagram: @terroresnocturnos_trn Instagram Emma Entrena: @emma.e_trn Instagram Silvia Ortiz: @sil_trn Instagram David Fernández Marcos: @davidfm55 Instagram The Gray: @thegray.art Facebook: Terrores Nocturnos Correo: terroresnocturnosradio@gmail.com Realizado por David Fernández Marcos Presentado por Emma Entrena y Silvia Ortiz Ilustración de TheGray.art Este episodio está patrocinado por Hayu. Dirígete a Hayu.com para comenzar tu prueba gratuita. --- Send in a voice message: https://anchor.fm/terroresnocturnos/message

Check out our new online discipleship course called CREATED Sexuality:  https://themessyreformation.jasonruis.com/the-hall-of-tyrannus/   Support us on Patreon: https://www.patreon.com/themessyreformation?fan_landing=true   Check out our website: https://themessyreformation.jasonruis.com   Check out the Abide Project:  https://www.abideproject.org   We love the Christian Reformed Church; we want to see reformation in our denomination; and we recognize that reformation is typically messy. So, we're having conversations with pastors throughout the CRC about what reformation might look like.   Intro Music by Matt Krotzer

As a critical building material for our Built Environment concrete makes up for some 8% of global emissions. Clare Tuboletsc, CEO of SmartCrete CRC, provides insights into the innovations now reshaping our approach to this age-old material, and the role of CRC in enabling the collaboration of an entire ecosystem to drive and deliver the changes needed.   

A new research paper was published in Oncotarget's Volume 13 on October 8, 2022, entitled, “In vitro chemotherapy-associated muscle toxicity is attenuated with nutritional support, while treatment efficacy is retained.” Muscle-wasting and treatment-related toxicities negatively impact prognosis of colorectal cancer (CRC) patients. Specific nutritional composition might support skeletal muscle and enhance treatment support. In this new in vitro study, researchers Liza A. Wijler, Francina J. Dijk, Hanil Quirindongo, Danielle A.E. Raats, Bram Dorresteijn, Matthew J.W. Furber, Anne M. May, Onno Kranenburg, and Miriam van Dijk, from University Medical Centre Utrecht, Danone Nutricia Research and Utrecht University, assessed the effect of nutrients eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), L-leucine, and vitamin D3 as single nutrients or in combination on chemotherapy-treated C2C12-myotubes and specific CRC-tumor cells. Using C2C12-myotubes, the effects of chemotherapy (oxaliplatin, 5-fluorouracil, oxaliplatin+5-fluorouracil and irinotecan) on protein synthesis, cell-viability, caspase-3/7-activity and lactic acid dehydrogenase (LDH)-activity were assessed. Addition of EPA, DHA, L-leucine and vitamin D3 and their combination (SNCi) were studied in presence of above chemotherapies. Tumor cell-viability was assessed in oxaliplatin-treated C26 and MC38 CRC cells, and in murine and patient-derived CRC-organoids. While chemotherapy treatment of C2C12-myotubes decreased protein synthesis, cell-viability and increased caspase-3/7 and LDH-activity, SNCi showed improved protein synthesis and cell viability and lowered LDH activity. The nutrient combination SNCi showed a better overall performance compared to the single nutrients. Treatment response of tumor models was not significantly affected by addition of nutrients. “This in vitro study shows protective effect with specific nutrition composition of C2C12-myotubes against chemotherapy toxicity, which is superior to the single nutrients, while treatment response of tumor cells remained.” DOI: https://doi.org/10.18632/oncotarget.28279 Correspondence to: Miriam van Dijk – Email: miriam.vandijk@danone.com Keywords: C2C12 myotubes, chemotherapy, chemotherapy-associated toxicity, colorectal cancer, nutrients, tumor (organoid) cells About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media: Twitter – https://twitter.com/Oncotarget Facebook – https://www.facebook.com/Oncotarget YouTube – www.youtube.com/c/OncotargetYouTube Instagram – https://www.instagram.com/oncotargetjrnl/ LinkedIn – https://www.linkedin.com/company/oncotarget/ Pinterest – https://www.pinterest.com/oncotarget/ LabTube – https://www.labtube.tv/channel/MTY5OA SoundCloud – https://soundcloud.com/oncotarget For media inquiries, please contact: media@impactjournals.com

Todo el mundo conoce el caso de los niños salvajes, niños humanos que fueron abandonados por sus padres, y criados por lobos, perros... Esta vez nuestra es Genie, una niña que no vivió entre animales, sino con un monstruo, con su padre. Muchísimas gracias por la participación a: - JESSICA DE JESÚS: @jessicaadjc (Twitter) @jesskidrauhl (Instagram) Por supuesto gracias a todos nuestros mecenas que nos habéis acompañado en esta tercera temporada ¡Sois los mejores! Camarzana1, José Manuel D. G., Consuelo, Laura D., Ramiro C., Samuel C., Ana C., Clara R., Lara M., Claudia, Xavito B., Laura, Iván De Benito P., Marcos M. V., Naiara G. G., TorpeKun, Míriam Z., Sara S. C., María Jesús B., Eva V., Paloma del Soterraño S. M., Ferran B. L., Fernando F. M., José Antonio M. H., Patri J., Sandra S. C., Antonio A., Sara D., Beatriz G., Mónica M., Maxbiag, Carmen S. S., Raquel., Rocio B., Alejandro L. G., Sebastian Q., Lorena R. T., Nox21, Andréa E., Víctor I., Alba R., Diego G., Raul M. G., Klap K., Miguel Ángel S. G., Julia E. S., Jonathan L. G., Noelia M., Jose C., David G. A., Virginia, Nardo1000, Diego C. A., Mayte S.M., Cynthia, Homero R. D. C., Desirée G. A., Miguel Ángel S., Andres C., Antonio S. M., Vero, Ana, Yaiza M. G., Piteas De Adunte, Manuel Jesús F. V., Ian T. A., Felix R. G., David Z., Jaime A. B., Natalia E. N., Pep V., Alejandro, Adrián A. C., Vicco S., Nico, Beatriz S., Juan Carlos V. P., Carla, Manuel G. C., Adrian, Ángel M. CRC., Moreyba S., Inés B. P., Patricia, Maciej Adrián R. A., Borja O. D. U., Pedro O. A., Daniela G., Blegoner P., Antonino D. M., Belén L. M., Andrea D., Robert, Marta G., Nonina, Cuervo Aqua, Tamara, Sara P., María R. M., Maite Y., Raquel N., Hellnukk, Iris, Miriam S. G., David G. A., Vanesa, Rut, Maria Merino P. D. R., Merce A., Sergio N., Maria Ignacia V., Laura S., Ezequiel Y., HumaDracobane, M Moar, Alvaro S. C., Aleix C., Regina G. M., Alejandra A., Alba, Erika T., Sandra A. L., Dahmm22, Guardi C. G., Alejandro F. P., Elena, Clara, Julia Salomon, Angel, Lionmind, Broke S., Thehob, Natanael C. S., Judith P. C., José A., David, Barbara P. J., Laura R., Patricia O. P., Arianna T. M., Juan L., Ana, Mariana D., Carlos Javier V. B., Sofía, Oscar Mata G. D. C., Marta B., Javier A. S., José Luis H. M., Chris, Ramiro, Victor N., Micaela, Joan Marc P. S., Miguel Diego A. C., Javier M. P., Mafdet23, Nina S., Yara, Patricia L. C., Laura N., Carmen, Bea T., Javier C., Marino Adolfo B. A., Dg, Bea G., Jorge H., Ismael G., Paula S., Nicole N., Rebeca P., Ana B., AlvaroArteaga27, Alexander J. G., Kumagoro 93, Carlos E., Sara C.Labrada, Jose Angel C. L., Sheila G., Francisca C. V., SYNL, Beto L. O., Luis M., Lucia G., Marcela V., Joey B., Mireia S., T. Kuznetsov, Patricia C. R., Rubén G., Vikki V., María Cecilia C. V., Srtanognog., Fran M., Eva L. F., Jose J., Inma, Juan Miguel P. P., marenostrum93, Moar Moar L., Victor E. ¿Quieres contactar con nosotros? Tiktok: @terroresnocturnos.trn Twitter: @TerroresN Instagram: @terroresnocturnos_trn Instagram Emma Entrena: @emma.e_trn Instagram Silvia Ortiz: @sil_trn Instagram David Fernández Marcos: @davidfm55 Instagram The Gray: @thegray.art Facebook: Terrores Nocturnos Correo: terroresnocturnosradio@gmail.com Realizado por David Fernández Marcos Presentado por Emma Entrena y Silvia Ortiz Ilustración de TheGray.art Este episodio está patrocinado por Hayu. Dirígete a Hayu.com para comenzar tu prueba gratuita. --- Send in a voice message: https://anchor.fm/terroresnocturnos/message

Happy Thanksgiving to all our Canadian listeners. Today, we have a really exciting episode that has been a long time coming. For this conversation we're joined by Pastors, Steve Swets and Dick Wynia who are well versed in this topic as they both have been heavily involved in unity discussions. We cover the history of these denominations, especially how it relates the CRC churches. We also discuss what conversations are happening currently and how we can move forward.  00:00 - Intro 04:50 - Dividing vs. Leaving 06:40 - The History 18:00 - Current State of the CRC 22:50 - Why didn't those leaving the CRC join the CanRC? 35:00 - How the denominations have changed 43:20 - What stalled these unity conversations? A BIG THANKS TO OUR OFFICIAL SPONSOR, TRIVAN! WE APPRECIATE YOU HELPING US MAKE THIS CONVERSATION POSSIBLE. BE SURE TO CHECK THEM OUT AT WWW.TRIVAN.COM  To keep up with the podcast, check out our website: https://www.realtalkpodcast.ca/ Follow us on Facebook and Instagram for updates, clips, and more!  Facebook: https://www.facebook.com/ReformedRealTalk Instagram: https://www.instagram.com/reformedrealtalk/ We'd love to hear from you. Please send us your questions, comments, or other feedback at reformedrealtalk@gmail.com. Thanks for listening! If you liked what you heard, please share this podcast with your family and friends!

Check out The Hall of Tyrannus: https://themessyreformation.jasonruis.com/the-hall-of-tyrannus/   Support us on Patreon: https://www.patreon.com/themessyreformation?fan_landing=true   Check out our website: https://themessyreformation.jasonruis.com   Check out the Abide Project:  https://www.abideproject.org   We love the Christian Reformed Church; we want to see reformation in our denomination; and we recognize that reformation is typically messy. So, we're having conversations with pastors throughout the CRC about what reformation might look like.   Intro Music by Matt Krotzer

Rev. John Bothof - Scripture: Genesis 24 Text: Genesis 24

Rev. John Bothof - Scripture: Psalm 119:57-64 Text: Psalm 119:57-64

If Garbriel Aponte's long list of credentials tells you anything, it would be that he is a life long learner and eager to master his professional skills. His long list of credentials includes, MSHIA, CPC, COC, CIC, CRC, CPMA, CDEO, CDEI, CCC, CHONC, RHIA, CCS, CCS-P, CDIP, CCDS, CCDS-O. When he's not preparing for his next exam he's serving AAPC members and medical coders across the world as a member of AAPC's National Advisor Board. Learn more about Gabriel in this edition of #iamaapc.

Hii leo katika Habari za UN Assumpta Massoi anakuletea Habari kwa Ufupi, Mada kwa Kina na Kujifunza Lugha ya Kiswahili. Katika Habari kwa Ufupi kuna haki za mtoto kuzingatiwa hasa wakati huu ambapo majanga ya kiasili na yanayosababishwa na binadamu  yanakengeua utekelezaji wa haki za mtoto. Suala la afya ya akili barani Afrika ambayo inachochea matukio ya kujiua ,na WHO imezindua kampeni maalum. Na kisha ni uzinduzi wa ripoti kuhusu matumizi ya matukio makubwa ya michezo ili kuimarisha afya ya mwili ya binadamu. Mada kwa kina ni kijana Jessica Mshama, Balozi wa vijana wa Jumuiya ya Afrika Mashariki akizungumzia alichojifunza wakati wa Mkutano wa ngazi ya juu wa  Umoja wa Mataifa kuhusu marekebisho ya mfumo wa elimu. Na kwenye kujifunza Kiswahili ni uchambuzi kutoka Kenya wa methali isemayo, Kinga na Kinga ndipo moto huwaka! Karibu

In this episode of Medsider Radio, we sat down with Yoav Kimchy, Founder and CTO of Check-Cap.Yoav has more than 20 years of experience in the development and management of innovative medical device companies. In 2005, he founded Check-Cap, a clinical-stage medical diagnostics company that aims to change the colorectal cancer (CRC) screening landscape with its C-Scan ingestible capsule, tracing, and imaging system. In this discussion, Yoav shares how early feedback from regulators can help streamline your development efforts, why you should shift your team as the company grows, and the importance of knowing when to lead and when to follow.Before we jump into the conversation, I wanted to mention a few things:If you're into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You'll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you're interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Yoav if you'd rather read it instead.

El caso de Kenneka Jenkins es uno de los casos sin cerrar en EEUU, con una teoría policial que explica que, la joven se metió en un congelador por accidente, pero... ¿Es esta toda la verdad? ¿Y si no fue un accidente? Muchísimas gracias a los actores que han participado en este capítulo: - GEMMA ESTEBAN - NOELIA GÓMEZ MARTÍN @noeliagomezfm (Instagram) @NoeliaGomezFM (Twitter) Por supuesto gracias a todos nuestros mecenas que nos habéis acompañado en esta tercera temporada ¡Sois los mejores! Camarzana1, José Manuel D. G., Consuelo, Laura D., Ramiro C., Samuel C., Ana C., Clara R., Lara M., Claudia, Xavito B., Laura, Iván De Benito P., Marcos M. V., Naiara G. G., TorpeKun, Míriam Z., Sara S. C., María Jesús B., Eva V., Paloma del Soterraño S. M., Ferran B. L., Fernando F. M., José Antonio M. H., Patri J., Sandra S. C., Antonio A., Sara D., Beatriz G., Mónica M., Maxbiag, Carmen S. S., Raquel., Rocio B., Alejandro L. G., Sebastian Q., Lorena R. T., Nox21, Andréa E., Víctor I., Alba R., Diego G., Raul M. G., Klap K., Miguel Ángel S. G., Julia E. S., Jonathan L. G., Noelia M., Jose C., David G. A., Virginia, Nardo1000, Diego C. A., Mayte S.M., Cynthia, Homero R. D. C., Desirée G. A., Miguel Ángel S., Andres C., Antonio S. M., Vero, Ana, Yaiza M. G., Piteas De Adunte, Manuel Jesús F. V., Ian T. A., Felix R. G., David Z., Jaime A. B., Natalia E. N., Pep V., Alejandro, Adrián A. C., Vicco S., Nico, Beatriz S., Juan Carlos V. P., Carla, Manuel G. C., Adrian, Ángel M. CRC., Moreyba S., Inés B. P., Patricia, Maciej Adrián R. A., Borja O. D. U., Pedro O. A., Daniela G., Blegoner P., Antonino D. M., Belén L. M., Andrea D., Robert, Marta G., Nonina, Cuervo Aqua, Tamara, Sara P., María R. M., Maite Y., Raquel N., Hellnukk, Iris, Miriam S. G., David G. A., Vanesa, Rut, Maria Merino P. D. R., Merce A., Sergio N., Maria Ignacia V., Laura S., Ezequiel Y., HumaDracobane, M Moar, Alvaro S. C., Aleix C., Regina G. M., Alejandra A., Alba, Erika T., Sandra A. L., Dahmm22, Guardi C. G., Alejandro F. P., Elena, Clara, Julia Salomon, Angel, Lionmind, Broke S., Thehob, Natanael C. S., Judith P. C., José A., David, Barbara P. J., Laura R., Patricia O. P., Arianna T. M., Juan L., Ana, Mariana D., Carlos Javier V. B., Sofía, Oscar Mata G. D. C., Marta B., Javier A. S., José Luis H. M., Chris, Ramiro, Victor N., Micaela, Joan Marc P. S., Miguel Diego A. C., Javier M. P., Mafdet23, Nina S., Yara, Patricia L. C., Laura N., Carmen, Bea T., Javier C., Marino Adolfo B. A., Dg, Bea G., Jorge H., Ismael G., Paula S., Nicole N., Rebeca P., Ana B., AlvaroArteaga27, Alexander J. G., Kumagoro 93, Carlos E., Sara C.Labrada, Jose Angel C. L., Sheila G., Francisca C. V., SYNL, Beto L. O., Luis M., Lucia G., Marcela V., Joey B., Mireia S., T. Kuznetsov, Patricia C. R., Rubén G., Vikki V., María Cecilia C. V., Srtanognog., Fran M., Eva L. F., Jose J., Inma, Juan Miguel P. P., marenostrum93, Moar Moar L., Victor E. ¿Quieres contactar con nosotros? Tiktok: @terroresnocturnos.trn Twitter: @TerroresN Instagram: @terroresnocturnos_trn Instagram Emma Entrena: @emma.e_trn Instagram Silvia Ortiz: @sil_trn Instagram David Fernández Marcos: @davidfm55 Instagram The Gray: @thegray.art Facebook: Terrores Nocturnos Correo: terroresnocturnosradio@gmail.com Realizado por David Fernández Marcos Presentado por Emma Entrena y Silvia Ortiz Ilustración de TheGray.art --- Send in a voice message: https://anchor.fm/terroresnocturnos/message

Sign up for our brand new 14-day Credit Hero Challenge.Hey credit heroes!Today's episode is a little bit different from usual.That's because over the weekend, I was lucky enough to have attended Funnel Hacking Live!For those of you who don't know, this is an event held by Russell Brunson and Clickfunnels, where we have learned most of our marketing secrets to be able to grow Credit Repair Cloud to the scale it is at now!And when I was there, I was awarded as the Bootstrapped Entrepreneur of the Year! This meant a whole lot to me personally, and in today's episode… I'm going to explain why.After receiving the award, I was invited onto the stage to tell my story with the audience… and in today's episode… I'm going to share it with you.So make sure to check it out!Key Takeaways:Intro (00:00)My award acceptance speech (07:23)How I got started in credit repair (13:22)How I grew CRC (16:59)How this was all possible (20:27)My two pieces of advice for entrepreneurs (24:51)Additional Resources:- Get a free trial to Credit Repair Cloud- Get my free credit repair training  Make sure to subscribe so you stay up to date with our latest episodes

Check out The Hall of Tyrannus: https://themessyreformation.jasonruis.com/the-hall-of-tyrannus/    Support us on Patreon: https://www.patreon.com/themessyreformation?fan_landing=true   Check out our website: https://themessyreformation.jasonruis.com   Check out the Abide Project:  https://www.abideproject.org   We love the Christian Reformed Church; we want to see reformation in our denomination; and we recognize that reformation is typically messy. So, we're having conversations with pastors throughout the CRC about what reformation might look like.   Intro Music by Matt Krotzer

Rev. John Bothof - Scripture: Psalm 119:49-56 Text: Psalm 119:49-56

Rev. John Bothof - Scripture: Genesis 23:1-20 Text: Genesis 23:1-20

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Douglas Rex, MD Colorectal cancer (CRC) is the second leading cause of cancer deaths in men and women, but it's also the most preventable form of internal cancer. To get the most up-to-date insights on how the latest screening recommendations can help us detect CRC earlier, Dr. Charles Turck speaks with Dr. Douglas Rex, Distinguished Professor Emeritus of Medicine at Indiana University School of Medicine.

Today's guests are Tamara Hicks, RN, CCS, CCDS, ACM-RN, CCDS-O, the director of clinical documentation excellence at Atrium Health Wake Forest Baptist in Winston-Salem, North Carolina, and Laurie Prescott, RN, MSN, CCDS, CCDS-O, CDIP, CRC, the interim director of ACDIS as well as the director of CDI education for HCPro. Today's show is part of the “Talking CDI” series. In every episode of this series, ACDIS Director of Programming Rebecca Hendren discusses CDI topics with guests including members of the ACDIS Advisory Board or other experienced CDI leaders from around the country to discuss strategic topics related to the state of the industry, where CDI is going, or opportunities for advancement. During today's show, Prescott discusses the fiscal year (FY) 2023 Inpatient Prospective Payment System (IPPS) final rule which goes into effect on October 1, 2022. To accompany the conversation, Prescott has provided a PowerPoint covering the notable changes, which can be accessed for free here. Our intro and outro music for the ACDIS Podcast is “medianoche” by Dee Yan-Kay and our ad music is “Take Me Higher” by Jahzzar, both obtained from the Free Music Archive. Have questions about today's show or ideas for a future episode? Contact the ACDIS team at acdis-inquiries@simplifycompliance.com. ACDIS update: Access the FY 2023 IPPS final rule PowerPoint (http://ow.ly/ASMa50KQst2) Register for the ACDIS Online: CDI Symposium for Outpatient Efforts, a virtual event happening December 6-8, 2022 (http://ow.ly/zauc50KQszc) Register for the 15th annual ACDIS national conference, happening May 8-11, 2023, in Chicago, Illinois (http://ow.ly/MtBV50KQsJl) 

¿Qué sentirías si supieras que entre los pasillos de tu facultad divagan almas en pena? ¿Que, en la silla sobre la que te sientas, hubo decenas de personas que murieron antes que tú? En este capítulo, las universidades encantadas. Muchísimas gracias a los actores que han participado en este capítulo: - ANDRÉS MORALEDA @amoraledag (Instagram y Twitter) - GEMMA ESTEBAN Por supuesto gracias a todos nuestros mecenas que nos habéis acompañado en esta tercera temporada ¡Sois los mejores! Camarzana1, José Manuel D. G., Consuelo, Laura D., Ramiro C., Samuel C., Ana C., Clara R., Lara M., Claudia, Xavito B., Laura, Iván De Benito P., Marcos M. V., Naiara G. G., TorpeKun, Míriam Z., Sara S. C., María Jesús B., Eva V., Paloma del Soterraño S. M., Ferran B. L., Fernando F. M., José Antonio M. H., Patri J., Sandra S. C., Antonio A., Sara D., Beatriz G., Mónica M., Maxbiag, Carmen S. S., Raquel., Rocio B., Alejandro L. G., Sebastian Q., Lorena R. T., Nox21, Andréa E., Víctor I., Alba R., Diego G., Raul M. G., Klap K., Miguel Ángel S. G., Julia E. S., Jonathan L. G., Noelia M., Jose C., David G. A., Virginia, Nardo1000, Diego C. A., Mayte S.M., Cynthia, Homero R. D. C., Desirée G. A., Miguel Ángel S., Andres C., Antonio S. M., Vero, Ana, Yaiza M. G., Piteas De Adunte, Manuel Jesús F. V., Ian T. A., Felix R. G., David Z., Jaime A. B., Natalia E. N., Pep V., Alejandro, Adrián A. C., Vicco S., Nico, Beatriz S., Juan Carlos V. P., Carla, Manuel G. C., Adrian, Ángel M. CRC., Moreyba S., Inés B. P., Patricia, Maciej Adrián R. A., Borja O. D. U., Pedro O. A., Daniela G., Blegoner P., Antonino D. M., Belén L. M., Andrea D., Robert, Marta G., Nonina, Cuervo Aqua, Tamara, Sara P., María R. M., Maite Y., Raquel N., Hellnukk, Iris, Miriam S. G., David G. A., Vanesa, Rut, Maria Merino P. D. R., Merce A., Sergio N., Maria Ignacia V., Laura S., Ezequiel Y., HumaDracobane, M Moar, Alvaro S. C., Aleix C., Regina G. M., Alejandra A., Alba, Erika T., Sandra A. L., Dahmm22, Guardi C. G., Alejandro F. P., Elena, Clara, Julia Salomon, Angel, Lionmind, Broke S., Thehob, Natanael C. S., Judith P. C., José A., David, Barbara P. J., Laura R., Patricia O. P., Arianna T. M., Juan L., Ana, Mariana D., Carlos Javier V. B., Sofía, Oscar Mata G. D. C., Marta B., Javier A. S., José Luis H. M., Chris, Ramiro, Victor N., Micaela, Joan Marc P. S., Miguel Diego A. C., Javier M. P., Mafdet23, Nina S., Yara, Patricia L. C., Laura N., Carmen, Bea T., Javier C., Marino Adolfo B. A., Dg, Bea G., Jorge H., Ismael G., Paula S., Nicole N., Rebeca P., Ana B., AlvaroArteaga27, Alexander J. G., Kumagoro 93, Carlos E., Sara C.Labrada, Jose Angel C. L., Sheila G., Francisca C. V., SYNL, Beto L. O., Luis M., Lucia G., Marcela V., Joey B., Mireia S., T. Kuznetsov, Patricia C. R., Rubén G., Vikki V., María Cecilia C. V., Srtanognog., Fran M., Eva L. F., Jose J., Inma, Juan Miguel P. P., marenostrum93, Moar Moar L., Victor E. ¿Quieres contactar con nosotros? Tiktok: @terroresnocturnos.trn Twitter: @TerroresN Instagram: @terroresnocturnos_trn Instagram Emma Entrena: @emma.e_trn Instagram Silvia Ortiz: @sil_trn Instagram David Fernández Marcos: @davidfm55 Instagram The Gray: @thegray.art Facebook: Terrores Nocturnos Correo: terroresnocturnosradio@gmail.com Realizado por David Fernández Marcos Presentado por Emma Entrena y Silvia Ortiz Ilustración de TheGray.art --- Send in a voice message: https://anchor.fm/terroresnocturnos/message

Support us on Patreon: https://www.patreon.com/themessyreformation?fan_landing=true   Check out our website: https://themessyreformation.jasonruis.com   Check out the Abide Project:  https://www.abideproject.org   We love the Christian Reformed Church; we want to see reformation in our denomination; and we recognize that reformation is typically messy. So, we're having conversations with pastors throughout the CRC about what reformation might look like.   Intro Music by Matt Krotzer

In the CRC, the sermon is at the center of the worship. So much of the service is centered around the sermon. Thankfully, the power in the sermon or the Word of God is not in the delivery or hearing of the Word. We continue our Holy Habits series, a series where we look at the different parts of our Sunday worship. This week we will look at the service of the Word. Rev. Jonker will preach and he will focus on Isaiah 55:10-11.

Videos : Those who speak out are shouted down until they are proved right, says Neil Oliver – 10:06 Gad Saad: Why Rational People Fall for ‘Parasitic' Ideas | American Thought Leaders CLIP – 9:11 Scientist Carl Sagan testifying to the U.S. Senate in 1985 on the greenhouse effect: – 2:44 Parent Eviscerates School Board Over Censorship– 4:59 Vitamin C supplementation associated with improved lung function in COPD Medical College of Lanzhou University (China), September 23 2022. The International Journal of Chronic Obstructive Pulmonary Disease published a systematic review and meta-analysis of clinical trials that found improvement in lung function among chronic obstructive pulmonary disease (COPD) patients who received vitamin C. The disease is characterized by airflow limitation and persistent respiratory symptoms. Ting Lei of Medical College of Lanzhou University in Lanzhou, China and associates identified 10 randomized, controlled trials that included a total of 487 adults with COPD for the meta-analysis. The trials compared lung function and/or antioxidant enzyme or nutrient levels of COPD patients who received vitamin C to a placebo or control group. The meta-analysis found improvement in forced expiratory volume in one second as a percentage (FEV1%, a measure of lung function) in association with vitamin C supplementation. When dosage was analyzed, it was determined that consuming more than 400 milligrams vitamin C per day was needed experience a significant benefit. The ratio of FEV1 to forced vital capacity (another lung function assessment), and levels of vitamin C and glutathione, both of which are antioxidants, also improved among participants who received vitamin C supplements. The authors remarked that oxidative stress, which is a disturbance of the oxidant to antioxidant balance, has been suggested as playing a role in the development of COPD. The current investigation is the first systematic review and meta-analysis to assess the effect of vitamin C supplementation in people with COPD. “We found that supplementing vitamin C to patients with COPD demonstrated vital clinical significance,” Lei and associates concluded. “Vitamin C supplementation could increase the levels of antioxidation in serum (vitamin C and glutathione) and improve lung function (FEV1% and FEV1/FVC), especially in patients treated with vitamin C supplementation greater than 400 mg/day.” Single Flavanoid (Found in 6 Foods) Reduces Cognitive Impairment Drastically Fourth Military Medical University (China), September 19, 2022 A singular flavanoid can protect the brain against cognitive deficit and other cellular damage, according to studies from the Fourth Military Medical University. The news comes from Xi'an, People's Republic of China, and shows great promise for those suffering from mental impairment due to Alzheimer's disease, vascular dementia, and other debilitating cognitive conditions. The study abstract concludes: “Our results provide new insights into the pharmacological actions of rutin and suggest that rutin has multi-targeted therapeutical potential on cognitive deficits associated with conditions with chronic cerebral hypoperfusion such as vascular dementia and Alzheimer's disease.” Rutin is a biologically active flavonoid found in the following foods:  Buckwheat – Possibly the best source of rutin, and much better than boiled oats, uncooked buckwheat leaf flower offers about 675 mg in a 1.1 cup serving. Uncooked buckwheat groats contain 230 mg of rutin per 1 kg, dark buckwheat flour has 218 mg per 1 kg and buckwheat noodles provide 78 mg. Elderflower Tea – When dried, the white flowers of the elderflower make a delicious and rutin-filled tea. According to the Czech Journal of Food Science, elderflower tea contains approximately 10.9g/kg of rutin per brewed cup. Amaranth Leaves – In Western cultures, most people are familiar with the edible seeds of amaranth, though in Chinese and Southeast Asian cooking the leaves are also gaining traction, partly due to their high rutin content. You can expect around 24.5g/kg from the dried leaves. Seeds only contain trace amounts of the important nutrient. Unpeeled Apples – Keep the peel on your apples to enjoy lots of rutin. Just be sure that they are organic, since apple peels are especially prone to pesticide build-up. Apple skins are 6x as powerful as the flesh at preventing high blood pressure due to this flavanoid, too. • Unfermented Rooibos Tea – While rooibos tea contains fewer antioxidants than black or green teas, it is a good source of rutin, providing around 1.69 mg/g. • Figs – These little gems contain about the same amount of rutin as apples, so be sure to add them to your diet. The scientists found that rutin works primarily through anti-inflammatory mechanisms, and reducing hypofusion in the brain. Resistance-breathing training found to lower blood pressure University of Colorado and University of Arizona, September 23, 2022 A team of researchers with members from the University of Colorado, the University of Arizona and Alma College, has found that resistance-breathing training can lower blood pressure as much as some medicines and/or exercises. The study is published in the Journal of Applied Physiology. Hypertension, also known as chronic high blood pressure, can lead to a wide variety of health problems, from loss of vision to strokes and heart attacks. For that reason, doctors take it seriously. Typically, patients are directed to modify their diet and to exercise more. If that does not fix the problem, medications are prescribed. In this new effort, the researchers looked into a new type of therapy to reduce blood pressure levels—resistance-breathing training. Resistance-breathing training involves breathing in and out of a small device, called, quite naturally, a POWERbreathe, every day for several minutes. The device forces the patient to use their breathing muscles to push and pull air through it, making them stronger. And that, the researchers found, also reduces blood pressure. The device has been in use for several years as a means to assist athletes, singers and people with weak lung muscles. Several groups of healthy volunteers practiced the training for a few minutes every day for six weeks. Each was breathed in and out with the device 30 times each session. Each of the volunteers had their blood pressure measured before and after the training. The researchers found a sustained average drop of 9 mmHg in systolic blood pressure (the top number in blood pressure readings)—normal pressure is defined as 120/80. They describe the change as significant, as much as some patients see with medication. They also note that it is similar to changes in many patients who begin an aerobic exercise regimen, such as walking, cycling or running. They suggest such training could be used by patients of all ages who are unable to exercise to lower their blood pressure. How To Maintain Peak Brain Health: Scientists Say It Comes Down To These 3 Factors Norwegian University of Science and Technology, September 23, 2022 What's the best way to maintain peak brain health as we age? There are countless studies detailing ways to prevent cognitive decline, so scientists in Norway sought to simplify the science of managing strong brain health to three recommendations. This report is something of a summation covering modern science's current understanding of how best to cultivate robust brain health. The team at NTNU cite 101 references to prior articles in this latest theoretical perspective paper. “Three factors stand out if you want to keep your brain at its best,” Prof. Sigmundsson adds. The three identified keys to strong brain health are: Physical exercise Social activity Strong, passionate interests and hobbies It's common knowledge that spending all day on the couch isn't healthy for the body, but physical activity is also key to brain health. “An active lifestyle helps to develop the central nervous system and to counteract the aging of the brain,” according to study authors. Researchers add that consistency is essential. Do your best to get in at least a little movement each and every day. Even if you work a sedentary job that requires lots of sitting, get moving every hour or so for just a few minutes at the very least. Some people are naturally more social than others, but researchers stress that no one is an island. Even if you prefer a quiet night in to attending a party, make an effort to stay in touch with the people who matter to you. Our brains thrive on social interactions and connections. “Relationships with other people, and interacting with them, contribute to a number of complex biological factors that can prevent the brain from slowing down,” Prof. Sigmundsson explains. Just like bicep curls help us build muscle, keeping the brain active promotes strong lifelong cognition. Consider taking up a new hobby, or learning a new skill. Perhaps most importantly, though, don't force it; find something you're actually passionate about. It's never too late in life to learn something new! “Passion, or having a strong interest in something, can be the decisive, driving factor that leads us to learn new things. Over time, this impacts the development and maintenance of our neural networks,” Prof. Sigmundsson says. “Brain development is closely linked to lifestyle. Physical exercise, relationships and passion help to develop and maintain the basic structures of our brain as we get older,” Prof. Sigmundsson concludes. Calcium supplements may support a healthy colon: Harvard study Harvard School of Public Health, September 18, 2022 Supplements of calcium or non-dairy products fortified with the mineral may reduce the risk of colorectal cancer, according to meta-analysis of prospective observational studies by researchers at Harvard School of Public Health. For every 300 mg increase in calcium from supplements was associated with a 9% reduction in risk, wrote NaNa Keum and her co-authors in the International Journal of Cancer . Every 300 mg increase in total calcium was associated with a similar reduction in risk (8%), they added. “Our findings have several important clinical and public health implications,” they explained. “First, according to the 2003 to 2006 National Health and Nutrition Examination Survey, a nationally representative cross-sectional survey in the U.S., median total calcium intake of adults aged over 50 years was approximately 650 mg/day for no calcium-supplement users and 1,000 mg/day for calcium-supplement users. “As the benefit of calcium intake on CRC is expected to continue beyond 1,000 mg/day, not only non-supplement users but also supplement users may further reduce their CRC risk through additional calcium intake.” “Second, while dairy products, especially milk, are the major sources of calcium in many countries, they are a substantial source of calories and contain potentially harmful factors such as saturated fat, hormones, and casein proteins. Since our analyses provide evidence for an equivalent benefit of dietary and supplementary calcium, the benefit of calcium on CRC risk may be obtained through supplements and non-dairy products fortified with calcium.” The Boston-based scientists conducted dose-response meta-analyses of 15 studies involving 12,305 cases of colorectal cancer and calcium intakes ranging from 250-1,900 mg/day. The studies varied in duration from 3.3 to 16 years. The data indicated that both total and supplemental calcium were associated with reductions in the risk of colorectal cancer. “In conclusion, both dietary and supplementary calcium intake may continue to decrease colorectal cancer risk beyond 1,000 mg/day,” wrote Keum and her co-authors. Yoga's Age-Defying Effects Confirmed by Science Defence Institute of Physiology and Allied Sciences (India), September 21st 2022 While yoga's longevity promoting effects have been the subject of legend for millennia, increasingly modern science is confirming this ancient technology for spiritual and physical well-being actually can slow aging and stimulate our regenerative potential. One particularly powerful study published lin the journal Age titled, “Age-related changes in cardiovascular system, autonomic functions, and levels of BDNF of healthy active males: role of yogic practice”, found that a brief yoga intervention (3 months) resulted in widespread improvements in cardiovascular and neurological function. Indian researchers studied healthy active males of three age groups (20-29, 30-39, and 40-49 years) by randomly assigning them to practice one hour of yoga daily for 3 months. The observed significant differences between the younger and older participants in the study, specifically: “Significantly higher values of heart rate (HR), blood pressure (BP), load in heart (DoP), myocardial oxygen consumption (RPP), and total cholesterol (TC) were noted in senior age group.” The yogic practice resulted in significant reductions in all of these parameters (HR, BP, DoP, RPP and TC). Also observed in the older participants were decreases in high frequency (HF), total power (TP), all time domain variables of heart rate variability (HRV), and skin conductance (SC) — all of which increased following yogic practice. Higher levels of catecholamines (“stress hormones”) and low frequency (LF) power of HRV were noted in advancement of age, both of which decreased following yogic practice. Additionally, the senior age group had highest levels of cortisol and adrenocorticotrophic hormone (ACTH), both of which decreased following yogic practice. Finally, brain-derived neurotropic factor (BDNF), serotonin, and dopamine were low in higher age group, but these increased following yogic practice; an indication of improved brain function and cognition. The researchers concluded: ‘This study revealed that yogic practices might help in the prevention of age-related degeneration by changing cardiometabolic risk factors, autonomic function, and BDNF in healthy male.” There are a number of promising studies revealing the age-defying potential of this ancient practice. Here are some additional benefits confirmed in 2014 alone: Age-Related Respiratory Problems: A 2014 study from the journal of Human Kinetics found that a 3 month yoga intervention in 36 elderly women (average age 63.1) significantly improved pulmonary (respiratory) function. Age-Related Brain Cognitive Decline: A review in the Journals of Gerontology, involving a two month Hatha yoga intervention in the elderly (average age 62.0) resulted in significant improvements in “executive function measures of working memory capacity and efficiency of mental set shifting and flexibility compared with their stretching-strengthening counterparts.” Age-Related Hormone Insufficiency: A study published in Evidence Based Complementary and Alternative Medicine found that a 3 month yogic intervention in men (average age 42.8) and women (average age 44.75) resulted in improvements in the level of growth hormone and DHEAS, two essential hormones that drop off precipitously as we age. Age-Related Sleep Problems: Astudy published in Alternatives Therapies in Health and Medicine found a 12 week yogic intervention (yoga 2x a week) resulted in significant improvements in the quality of sleep in older individuals (average age 60). Age-Related Depression: From the Chinese Journal of Nursing found that not only did yoga improve sleep as found in the study above but also significantly reduced the depressive symptoms of elderly participants…after 6 months. “ This is just a small sampling of the literature. There is older research revealing that yoga has even more benefits for aging populations.

The Hall of Tyrannus: https://themessyreformation.jasonruis.com/the-hall-of-tyrannus/   Support us on Patreon: https://www.patreon.com/themessyreformation?fan_landing=true   Check out our website: https://themessyreformation.jasonruis.com   Check out the Abide Project:  https://www.abideproject.org   We love the Christian Reformed Church; we want to see reformation in our denomination; and we recognize that reformation is typically messy. So, we're having conversations with pastors throughout the CRC about what reformation might look like.   Intro Music by Matt Krotzer

In this episode I invite my special guest Christine Hall CHC (AAPC Instructor) CPC , CPB, CPMA, CRC, CEMC, CPC-I to discuss the Global Package. We will discuss the proposed revisions by CMS and the history of it since 1992. Are we ready for a revision? Let's find out What changes have technology and advances in medicine brought us? Are you getting involved and sharing what challenges your practice is facing? Specialty Specific Global Care for Orthopedics and Dermatology Is your EMR up the challenge? Using Subject Matter experts to improve operations and discover missed opportunities costing your practice Could revising the global package lead to better patient care? Check out some great resources: Global Package FAQ Global Surgery Indicators RAND Report CMS-1751-F Contact jmcnamara@oncospark.com for more information on improving your operations with coding and revenue challenges --- Send in a voice message: https://anchor.fm/healthcrossroads/message

La madrugada del 31 de agosto de 1997 el mundo se paralizó ante un acontecimiento histórico, la muerte de Diana de Gales, y que actualmente, deja más dudas sobre cómo ocurrió aquel fatídico accidente, y quién dio la orden... Muchísimas gracias a la actriz de doblaje que ha participado: - ALEJANDRA CARRIL @aleejandracv (Twitter) @alejandraaacv (Instagram) Por supuesto gracias a todos nuestros mecenas que nos habéis acompañado en esta tercera temporada ¡Sois los mejores! Camarzana1, José Manuel D. G., Consuelo, Laura D., Ramiro C., Samuel C., Ana C., Clara R., Lara M., Claudia, Xavito B., Laura, Iván De Benito P., Marcos M. V., Naiara G. G., TorpeKun, Míriam Z., Sara S. C., María Jesús B., Eva V., Paloma del Soterraño S. M., Ferran B. L., Fernando F. M., José Antonio M. H., Patri J., Sandra S. C., Antonio A., Sara D., Beatriz G., Mónica M., Maxbiag, Carmen S. S., Raquel., Rocio B., Alejandro L. G., Sebastian Q., Lorena R. T., Nox21, Andréa E., Víctor I., Alba R., Diego G., Raul M. G., Klap K., Miguel Ángel S. G., Julia E. S., Jonathan L. G., Noelia M., Jose C., David G. A., Virginia, Nardo1000, Diego C. A., Mayte S.M., Cynthia, Homero R. D. C., Desirée G. A., Miguel Ángel S., Andres C., Antonio S. M., Vero, Ana, Yaiza M. G., Piteas De Adunte, Manuel Jesús F. V., Ian T. A., Felix R. G., David Z., Jaime A. B., Natalia E. N., Pep V., Alejandro, Adrián A. C., Vicco S., Nico, Beatriz S., Juan Carlos V. P., Carla, Manuel G. C., Adrian, Ángel M. CRC., Moreyba S., Inés B. P., Patricia, Maciej Adrián R. A., Borja O. D. U., Pedro O. A., Daniela G., Blegoner P., Antonino D. M., Belén L. M., Andrea D., Robert, Marta G., Nonina, Cuervo Aqua, Tamara, Sara P., María R. M., Maite Y., Raquel N., Hellnukk, Iris, Miriam S. G., David G. A., Vanesa, Rut, Maria Merino P. D. R., Merce A., Sergio N., Maria Ignacia V., Laura S., Ezequiel Y., HumaDracobane, M Moar, Alvaro S. C., Aleix C., Regina G. M., Alejandra A., Alba, Erika T., Sandra A. L., Dahmm22, Guardi C. G., Alejandro F. P., Elena, Clara, Julia Salomon, Angel, Lionmind, Broke S., Thehob, Natanael C. S., Judith P. C., José A., David, Barbara P. J., Laura R., Patricia O. P., Arianna T. M., Juan L., Ana, Mariana D., Carlos Javier V. B., Sofía, Oscar Mata G. D. C., Marta B., Javier A. S., José Luis H. M., Chris, Ramiro, Victor N., Micaela, Joan Marc P. S., Miguel Diego A. C., Javier M. P., Mafdet23, Nina S., Yara, Patricia L. C., Laura N., Carmen, Bea T., Javier C., Marino Adolfo B. A., Dg, Bea G., Jorge H., Ismael G., Paula S., Nicole N., Rebeca P., Ana B., AlvaroArteaga27, Alexander J. G., Kumagoro 93, Carlos E., Sara C.Labrada, Jose Angel C. L., Sheila G., Francisca C. V., SYNL, Beto L. O., Luis M., Lucia G., Marcela V., Joey B., Mireia S., T. Kuznetsov, Patricia C. R., Rubén G., Vikki V., María Cecilia C. V., Srtanognog., Fran M., Eva L. F., Jose J., Inma, Juan Miguel P. P., marenostrum93, Moar Moar L., Victor E. ¿Quieres contactar con nosotros? Tiktok: @terroresnocturnos.trn Twitter: @TerroresN Instagram: @terroresnocturnos_trn Instagram Emma Entrena: @emma.e_trn Instagram Silvia Ortiz: @sil_trn Instagram David Fernández Marcos: @davidfm55 Instagram The Gray: @thegray.art Facebook: Terrores Nocturnos Correo: terroresnocturnosradio@gmail.com Realizado por David Fernández Marcos Presentado por Emma Entrena y Silvia Ortiz Ilustración de TheGray.art --- Send in a voice message: https://anchor.fm/terroresnocturnos/message

Support us on Patreon: https://www.patreon.com/themessyreformation?fan_landing=true   Check out our website: https://themessyreformation.jasonruis.com   Check out the Abide Project:  https://www.abideproject.org   We love the Christian Reformed Church; we want to see reformation in our denomination; and we recognize that reformation is typically messy. So, we're having conversations with pastors throughout the CRC about what reformation might look like.   Intro Music by Matt Krotzer

Tom Tilley has been known for over 15 years around Australian music circles and media, working as a journalist on Triple J's Hack program, the Australian ABC and for Channel 9.  And while his friends and colleagues knew he'd grown up in a religious home and church, they didn't really understand. So Tom released a book this year called Speaking in Tongues, and he joins me and Fiona who was also a CRC kid (see A Pentecostal Agenda) to talk about writing that book and what this coming out has been like!  It's a very thoughtful and revealing conversation about a young man finding his way and now, looking back at how he got there in the face of unusual barriers.  See the book giveaway on Facebook and Instagram too! Come chat!  producer: Kimberly Robinson

Gastrointestinal cancer experts Dr. Aparna Parikh and Dr. Kristin Ciombor discuss the treatment implications of the phase 3 PARADIGM trial and other advances in colorectal cancer with guest host and ASCO Daily News Associate Editor, Dr. Shaalan Beg.   TRANSCRIPT Dr. Shaalan Beg: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Shaalan Beg, your guest host of the ASCO Daily News Podcast today. I'm an adjunct associate professor at UT Southwestern's Simmons Comprehensive Center and vice president of Oncology at Science 37. I'm delighted to welcome Dr. Aparna Parikh, and Dr. Kristen Ciombor to the podcast today. Dr. Parikh is an assistant professor of Medicine at Harvard University and a GI medical oncologist at the Mass General Hospital Cancer Center. Dr. Ciombor is an associate professor of Medicine and GI medical oncologist at the Vanderbilt University Medical Center. Today, we'll be discussing exciting new approaches using EGFR inhibitors as frontline therapy in colorectal cancer, and promising advances with immune therapy in the treatment of rectal cancer. Our full disclosures are available in the show notes, and disclosures of all guests on the podcast can be found in our transcripts at: asco.org/podcasts. Dr. Parikh, and Dr. Ciombor, it's great to have you on the podcast today. Dr. Aparna Parikh: Thanks so much. Dr. Kristen Ciombor: Thanks so much for having us. Dr. Shaalan Beg: We've seen some exciting advances in GI oncology this year. Let's start with colorectal cancer. Dr. Parikh, there have been many trials looking to compare EGFR and VEGF inhibitors in colorectal cancer. We've heard about the IDEA studies, the FIRE trials, and CALGB 80405. At the 2022 ASCO Annual Meeting, we heard the results of the PARADIGM trial. Have we finally answered the question of when to use EGFR inhibitors as frontline therapy for colorectal cancer? Dr. Aparna Parikh: Thanks so much, Dr. Beg, for this great question. It has been a really exciting year for colorectal cancer across the board. So, the anti-EGFR story is really interesting and has evolved. And maybe just for a little bit of background, we know that colorectal cancer originating from both the right and left side of the colon differ. So, they differ embryologically, and epidemiologically; there are different genetic and molecular aspects to right and left sides of colon cancers. And we have learned over time that in the era of targeted therapy, the primary tumor location has been found to play a very important role, not only in the prognosis of patients but to predict treatment response. We know that patients that have left-sided colon cancers-- and when we think about left-sided colon cancers, we think about cancers that originate from the splenic flexure and descending colon, sigmoid colon, rectosigmoid junction, and sometimes include the rectum in this as well. The rectals have slightly different molecular features than distal colons. And we know that these left-sided patients, overall, have better survival benefits than patients that have right-sided CRC. And that includes again, cecum, ascending colon, hepatic flexure, and transverse colon. So, we know that that had prognostic implications, but what about the predictive implications? And with ASCO, we saw some really exciting data with the PARADIGM study, as Dr. Beg highlighted. We have seen many examples in the past showing the predictive power of anti-EGFR therapy, and anti-EGFR therapy showing a detriment for patients on the right side of the colon. But all these results historically have been obtained by retrospective analysis. So, retrospective analysis of the pivotal CALGB 80405 study, which is the first-line biologic trial. FIRE-3, which is a similar study, but done out of Europe, and KRYSTAL. So all these studies show the same finding but were all obtained basically by retrospective analysis. And what we saw with PARADIGM this year, which is exciting to see, is that this was the first prospective trial to test the superiority of an anti-EGFR inhibitor panitumumab versus bevacizumab in combination with standard doublet first-line chemotherapy for patients that were RAS-wild type. I guess I forgot to mention that again, anti-EGFR therapies are only eligible for patients that are RAS-wild type. We know that RAS-mutant patients and RAS, KRAS HRAS patients don't respond to anti-EGFR therapy. So, the study was looking at RAS-wild type patients, and again, asking the question “was panitumumab better than bevacizumab in combination with chemotherapy for these RAS-wild type patients and for left-sided tumors?” It was a multicenter trial done in Japan-- and I always commend the Japanese on their work and their designs and ability to do these studies that ask really important questions. And, overall survival was the primary endpoint of the study in patients with left-sided tumors, but they also did a full set analysis including patients that didn't have left-sided tumors. They had 823 randomized patients. Many patients, a handful did not receive per-protocol treatment, and some were excluded for other reasons relating to inclusion criteria. And they had 400 patients that ultimately received panitumumab and 402 patients that received bevacizumab in the full set analysis. And of those patients, there were 312 and 292 respectively had left-sided tumors. And although the PFS was comparable between the treatment group, we saw that panitumumab in the left-sided patients actually did improve the OS in both patient populations. But when you looked at the left-sided tumors, the difference was 37.9 versus 34.3 months meeting statistical significance. So, this was an exciting study because it confirmed prospectively what we have seen time and time again, and really behooves us to do early biomarker testing and know RAS status early for these patients with right-sided tumors, as they do derive benefit from anti-EGFR. Maybe I'll just pause there and open it up for more questions or comments from Dr. Ciombor as well. Dr. Kristen Ciombor: Yeah, Dr. Parikh, I thought these data were encouraging. And as you mentioned, the first prospective data that we have in this setting now that we know this primary tumor sidedness matters. Just on a practical note, what do you do in practice? Do you give a lot of anti-EGFR in the first-line? I find that the toxicity can be challenging sometimes and patients may not want to do that. So, it leaves us in a quandary sometimes. Dr. Aparna Parikh: Yeah. So, what's interesting and I don't think we have this data clearly answered yet is, I had, especially for kind of a fit patient-- with the previous data that we've seen with TRIBE and others showing a survival benefit with triplet chemotherapy for first-line therapy, my inclination had actually been to prefer triplet-- and we know that triplet and anti-EGFR toxicity-wise is really, really tough to manage, and really no benefit there that we've seen with OS or PFS, even though you maybe do get a little bit of a better response rate with that. And so where I have sort of struggled is triplet versus just doing first-line doublet plus anti-EGFR. You know, we are not having a discussion about triplet today, but we also saw some data at ASCO showing that perhaps the benefit of the triplet, with the triplet study, is not as much as we had hoped it would've been too. So, it's a good question. I do tend to prefer triplet, I guess, overall, for the healthy, good performance status patient. And then, if not, then doublet. And we, unfortunately, don't have kind of rapid EGFR testing, we're pushing for that. In practice, I think having RAS/RAF status up front would be entirely helpful. It's lumped into our pan-tumor profiling, comprehensive genomic panels. We get microsatellite instability (MSI) status, which I know we'll talk about here next right away. But I think another reason that oftentimes we don't add it right away, is because we don't have the RAS status right away. So, you just start with a doublet and you may end up sneaking it on later. And then, I'd love to, maybe in another podcast, where we can discuss second-line anti-EGFR therapies and what people do in practice for those right-sided patients should they never get anti-EGFR and later-lines of therapy too. And I would argue, perhaps not, because we do see some patients that do benefit, but it can be challenging sometimes with a fresh new patient to make these decisions. But at least, feel encouraged that we're doing the right thing by adding anti-EGFR therapy if they can tolerate it for the left-sided RAS-wild type patient. How about you? What do you do? Dr. Kristen Ciombor: Yeah. Largely, it's a great question. And I don't love giving anti-EGFR therapy. We have an additional issue where I am geographically in that we don't ever give cetuximab because of the high rates of an infusion reaction. So, we pretty much stick to panitumumab and are glad to have that option. But I have started to talk to patients about toxicity and I'm really upfront with the survival data. And it's interesting how people choose differently in terms of what's important to them. And whereas a few extra months in the overall survival may be overshadowed by the toxicity that they have to go through to accomplish that. So, it's good to have many options though, and that's the important thing, and I think the takeaway, as well. Dr. Shaalan Beg: So, kind of brings it back to the fundamentals of practicing medicine, right? Bringing our patients and giving them the options that are most available to them. But I'm going to ask both of you one by one: So, if we have our patient with left-sided colorectal cancer, known as KRAS RAS-wild type, do you recommend EGFR therapy and VEGF therapy and allow the patients to decide, or do you feel that we decide if their profile is such that we should continue with VEGF therapy instead? Dr. Ciombor, do you want to go first? Dr. Kristen Ciombor: Yeah, I think both are good options. I don't only do bevacizumab in the first-line by any means because we do have that survival data. It mostly comes down to a discussion with the patient in terms of toxicities and survival and how well those balance out. Dr. Aparna Parikh: Yeah, very similar. I think we have also gotten a little bit more adept at managing toxicity. I'm pretty aggressive about prophylaxis with even doxy and topicals for managing the rash. And so, for some of my younger patients who are wanting to be "aggressive" and want the exposure to anti-EGFR early but are still very mindful of how it's impacting their day-to-day semblance of self, especially for the younger patients, try to be very proactive about side effect management. And then, of course, we have the patients that have the electrolyte wasting and things too that sometimes if it's bad, we are stuck with infusions frequently and you may end up dropping for those patients. But I think the rash at least I feel like for most patients we can manage if you're aggressive about it too. And I think we have gotten better at that than we were many years ago. Dr. Kristen Ciombor: Never thought we'd be dermatologists, did we? In training, that was definitely not a path I was good at. Dr. Shaalan Beg: Dermato-Oncology, rapidly growing field. So, Dr. Ciombor, the rectal cancer space has evolved very rapidly in recent years, especially when we hear about total neoadjuvant therapy, short-course radiation, watch-and-wait, for those with complete clinical responses. So at ASCO this year, we heard results on immune therapy and rectal cancer. Can you summarize where we are with immune therapy and rectal cancer? Dr. Kristen Ciombor: So, yes. We heard a lot this year at ASCO; both at ASCO GI and ASCO, from the Memorial group and Dr. Cercek's group. And this has been a really exciting advance that we're starting to see and potentially paradigm-shifting data. So, we know-- as you mentioned, that our treatment of rectal cancer, specifically, locally advanced rectal cancer has changed a lot in the last few years with a shift to more Total Neoadjuvant Therapy. And what the Memorial data showed was that for the patients who have microsatellite instability or mismatch repair deficiency, which admittedly, is a small group, but certainly ones that we see in clinic, those patients, on their trial were treated with six months of dostarlimab as neoadjuvant therapy prior to any other treatment; before radiation, surgery, et cetera, and no chemotherapy. And what they found was that actually, six months of dostarlimab in the first 14 evaluable patients actually induced a 100% clinical complete response rate. So, it's really unheard of in most of our trials to see 100%. And I think that caught everyone's attention for sure. I think we have to keep in mind who these patients were and are because they are currently being followed. So, for instance, these were patients that had pretty bulky node-positive disease, almost all these patients did. These were not really early-stage tumors. We did see that 100% were BRAF-wild type, so it does tell us maybe this is not completely the population that we're all seeing when we do see microsatellite instability since we see a lot of sporadic tumors with BRAF mutations. But on the whole, I mean, these were all MSI-high patients and treated with dostarlimab; the six months, that was the total amount of treatment that they received, though a few patients achieved that clinical complete response earlier at about three months, at the three-month reassessment. And what the clinical complete response rate was, was looking both radiographically, as well as endoscopically, and not seeing any sign of residual tumor. I think the important thing here is that median follow-up is still pretty short. There are a few patients who are approaching now two years past that dostarlimab therapy and have not had tumor recurrence, but overall, the median follow-up is still quite short. So, I think we do need to continue to follow these patients. We don't have overall survival data yet either. I think we still have a lot to learn, but this is a very encouraging start and certainly, something that could be really treatment-changing for these patients, which again, as Dr. Parikh was saying, we need this molecular profiling early to make treatment decisions right off the bat, not even only for metastatic now, but even for these locally-advanced rectal cancer patients. Because if you think about it, we've all taken care of patients who have to go through chemoradiation, and chemo, and surgery, and have a lot of morbidity from those treatments so that even if you cure them, they're left with a lot of toxicity. So, if we could avoid some of that, even potentially, surgery, that would be wonderful. But I do caution that this is not the standard of care yet. This is only based on 14 patients with short follow-ups at the current time. But the trial is ongoing, and there are other trials open in this space for patients who don't live in New York or can't get to New York. And for instance, ECOG-ACRIN study 2201 is treating these same patients with nivo and ipi, as opposed to dostarlimab. And that trial is open in about 80 sites now across the US. So hopefully, geographically near all of these patients. Dr. Shaalan Beg: I think a lot of us and a lot of our listeners, that Monday after the results were announced on ASCO had our phone lines and our patient secure messaging lines blowing up. Dr. Kristen Ciombor: We should have warned our nurses and our treatment teams that they would be fielding these questions, yes. On one hand, it's wonderful that our data and the science is getting out to patients. But I think we also have to be really careful as to what is reaching them because many of them didn't realize it was for this subset of patient populations. But great that they're asking those questions and wondering-- being advocates for themselves too. Dr. Shaalan Beg: You use the term clinical complete response. Can you talk about how we determine someone has a complete clinical response and what their follow-up looks like? Dr. Kristen Ciombor: Yeah. In the context of this study, it was actually, as I mentioned, it was both radiographic complete response, as well as endoscopic. So that's one thing that is a little bit tricky when you think about surveillance of these patients. So, it requires a lot, both in frequent surveillance, MRIs, FLEX SIGs often, digital rectal exams, sometimes doing PET scans or CTs, and patients who-- not only on this kind of study but also in non-operative management; watch-and-wait - really have to commit to very close, very frequent follow-up because if the cancer recurs, we don't want to miss that and lose our chance to cure them. So I think that's a little bit different everywhere, how that watch-and-wait approach really manifests, but I think we're learning how to do that, and working in a multidisciplinary group to make sure that patients get the surveillance that they need. Dr. Aparna Parikh: Yeah. I totally agree. If we offer, for the MSI-high patients, if we ultimately end up offering neoadjuvant immunotherapy-- and actually, I'm looking forward to your study, Dr. Ciombor, too, I think the monotherapy versus doublet, too, is going to come up for these patients. But I had a patient just a week or two ago that was starting on this approach with neoadjuvant immunotherapy, but for now, as a group, if we're proceeding down that and they do get a clinical complete response, we're deciding to forego even the radiation and surgery. We're following what they did in the OPRA study, which was pretty aggressive surveillance on the backend, both with direct visualization and MRIs, and you're seeing these patients every three months or so. Dr. Shaalan Beg: Well, thank you Dr. Ciombor and Dr. Parikh for sharing some valuable insights with us on the podcast today. Dr. Aparna Parikh: Thanks so much for having us. It was a lot of fun. Dr. Kristen Ciombor: Thanks for having us on. Dr. Shaalan Beg: And thank you to our listeners for your time today. If you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review and subscribe, wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Kristen Ciombor @KristenCiombor Dr. Aparna Parikh @aparna1024   Dr. Shaalan Beg @ShaalanBeg Listen to additional episodes on advances in GI oncology: Novel Therapies in GI Oncology at ASCO22 ASCO22: Key Posters on Advances in GI Oncology Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Shaalan Beg: Employment: Science 37 Consulting or Advisory Role: Ipsen, Array BioPharma, AstraZeneca/MedImmune, Cancer Commons, Legend Biotech, Foundation Medicine Research Funding (Inst.): Bristol-Myers Squibb, AstraZeneca/MedImmune, Merck Serono, Five Prime Therapeutics, MedImmune, Genentech, Immunesensor, Tolero Pharmaceuticals Dr. Kristen Ciombor: Consulting or Advisory Role: Merck, Pfizer, Lilly, Seagen, Replimune, Personalis Research Funding (Inst.): Pfizer, Boston Biomedical, MedImmune, Onyx, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Incyte, Amgen, Sanofi Recipient, Bristol-Myers Squibb, Array BioPharma, Incyte, Daiichi Sankyo, Nucana, Abbvie, Merck, Pfizer/Calithera, Genentech, Seagen Travel, Accommodations, Expenses Company: Array Dr. Aparna Parikh: Stock and Ownership Interests: C2i genomics Consulting or Advisory Role: Eli Lilly, Natera, Checkmate Pharmaceuticals, Pfizer, Roche/Genentech, Inivata, Biofidelity, Guardant Health Research Funding(Inst.): PMV Pharma, Plexxikon, Bristol-Myers Squibb, Genentech, Guardant Health, Array, Eli Lilly, Novartis Pharmaceuticals UK Ltd., PureTech, Mirati Therapeutics, Daiichi Sankyo